Lung Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034

Lung Cancer Diagnostics Market Summary

Overview:

• The Lung Cancer Diagnostics market is estimated at USD 3.5 billion in 2025 and is projected to reach USD 6.9 billion by 2034. Growth is anchored in the rising global incidence of lung cancer, the expansion of low-dose computed tomography screening, and the growing role of biomarker and molecular testing in guiding targeted therapy and immunotherapy.
• The global Lung Cancer Diagnostics market is growing at a CAGR of 7.8% during the forecast period from 2026 to 2034.
• By test type, the imaging tests segment dominated the Lung Cancer Diagnostics market with a 50% share in 2025.
• By product type, the reagents and kits segment dominated the Lung Cancer Diagnostics market with a share of 65% in 2025.
• By technology, the imaging segment dominated the Lung Cancer Diagnostics market with a share of 36% in 2025.
• By end-user, the hospitals segment dominated the Lung Cancer Diagnostics market with a share of 48% in 2025.
• North America dominated the global Lung Cancer Diagnostics market revenue with a share of 42% in 2025, representing the highest regional market share globally.

Lung cancer diagnostics comprises the tests, instruments, reagents, and kits used to screen for, diagnose, stage, and guide the treatment of lung cancer, the leading cause of cancer death worldwide. The category spans imaging tests, including low-dose computed tomography screening, diagnostic computed tomography, positron emission tomography, chest radiography, and magnetic resonance imaging, and laboratory and molecular tests, including biopsy and cytology, immunohistochemistry, molecular and biomarker testing, liquid biopsy, and sputum cytology. Diagnostic technologies include imaging, bronchoscopy, histopathology and immunohistochemistry, polymerase chain reaction, next-generation sequencing, and liquid biopsy, supplied by companies such as Roche through Ventana and Foundation Medicine, Thermo Fisher Scientific through Oncomine, QIAGEN through TheraScreen, Agilent through Dako, and molecular and liquid biopsy specialists including Guardant Health, Illumina, and Natera. Biomarker testing, including EGFR, ALK, ROS1, KRAS G12C, BRAF, MET, RET, NTRK, and PD-L1, is central to guiding targeted therapy and immunotherapy in non-small cell lung cancer. Testing is performed in hospitals, diagnostic and reference laboratories, imaging and diagnostic centers, and academic and research institutes. Over the past decade, the field has advanced from imaging and histopathology toward comprehensive molecular profiling, companion diagnostics, and liquid biopsy that enable precision oncology. Driven by the rising incidence of lung cancer, the expansion of screening, and the growth of biomarker-guided therapy, lung cancer diagnostics is one of the largest and most dynamic segments of oncology diagnostics.

Lung Cancer Diagnostics Market Key Growth Drivers

• The rising global incidence of lung cancer, the leading cause of cancer death worldwide, is expanding demand for diagnostic and molecular testing.
• The expansion of low-dose computed tomography screening programs, supported by evidence and screening recommendations, is increasing early detection and diagnostic testing.
• The growing role of biomarker and companion diagnostic testing, including EGFR, ALK, ROS1, KRAS G12C, and PD-L1, is expanding molecular testing to guide targeted therapy and immunotherapy.
• The rapid growth of liquid biopsy and comprehensive next-generation sequencing is expanding minimally invasive and comprehensive molecular profiling.
• Technological advances, including artificial intelligence-assisted imaging and pathology, are improving detection, characterization, and precision diagnosis.
• Rising healthcare access, imaging capacity, and laboratory infrastructure in emerging markets are broadening the global demand for lung cancer diagnostics.
• The convergence of rising incidence, expanding screening, and biomarker-guided therapy is expected to sustain strong growth in the global Lung Cancer Diagnostics market through 2034.

Key Companies in Lung Cancer Diagnostics Market

The competitive landscape is led by the following active developers and manufacturers of lung cancer diagnostics instruments, reagents, and kits:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Abbott Laboratories
• Natera, Inc.
• Danaher Corporation
• Biodesix, Inc.

Factors Contributing to the Growth of the Lung Cancer Diagnostics Market

Market Drivers

Rising Global Incidence of Lung Cancer

The rising global incidence of lung cancer is the foundational driver of lung cancer diagnostics demand. According to the International Agency for Research on Cancer, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, with roughly 2.5 million new cases and 1.8 million deaths each year, driven substantially by tobacco use and, increasingly, by other risk factors including air pollution. Every suspected and diagnosed case requires imaging, biopsy or cytology, and increasingly comprehensive biomarker testing for diagnosis, staging, and treatment planning, generating sustained demand for diagnostics. The high incidence and mortality of lung cancer, and the resulting emphasis on earlier detection and precision treatment, drive extensive diagnostic activity. As the global burden of lung cancer persists and molecular testing becomes standard, demand for lung cancer diagnostics continues to grow, reinforcing sustained market growth throughout the forecast period.

Expansion of Low-Dose Computed Tomography Screening

The expansion of low-dose computed tomography screening is a significant driver of lung cancer diagnostics demand. Evidence from large trials has demonstrated that low-dose computed tomography screening reduces lung cancer mortality in high-risk populations, and screening recommendations, including those from the United States Preventive Services Task Force, have broadened eligibility to larger populations of current and former smokers. The growth of organized and opportunistic screening programs increases the volume of imaging and the downstream diagnostic workup of detected nodules, including biopsy and molecular testing. Screening drives early detection, when treatment is more effective, and expands the diagnostic pathway. As screening programs expand across the United States, Europe, and other regions, and as eligibility and participation grow, low-dose computed tomography screening is expected to be an important driver of lung cancer diagnostics demand across the forecast period.

Market Restraints

Despite strong momentum, the Lung Cancer Diagnostics market faces material constraints. The late-stage presentation of many lung cancers, and the still-limited uptake and eligibility of screening in many regions, constrain early diagnosis. The invasive nature and risk of tissue biopsy, and the frequent insufficiency of tissue for comprehensive molecular testing, can limit testing, although liquid biopsy mitigates this challenge. Reimbursement and cost-containment pressures constrain testing volumes and the adoption of newer, higher-cost comprehensive sequencing and liquid biopsy tests in some settings, and coverage varies across payers and regions. Test standardization and access to comprehensive biomarker testing vary, and underuse of guideline-recommended molecular testing persists in some settings. A shortage of trained specialists in radiology, pathology, pulmonology, and molecular diagnostics can constrain capacity and interpretation. Rigorous and evolving regulatory requirements for in vitro diagnostic and companion diagnostic devices, including the European In Vitro Diagnostic Regulation and Food and Drug Administration pathways, add cost and complexity to product development and market entry. Finally, uneven imaging and laboratory infrastructure, limited screening, and affordability constraints in emerging markets can restrict access and adoption across parts of the forecast period.

Lung Cancer Diagnostics Market Segment Analysis

The Lung Cancer Diagnostics Market is segmented by test type (imaging tests, laboratory tests), product type (reagents and kits, instruments), technology (imaging, bronchoscopy, histopathology and immunohistochemistry, molecular diagnostics, liquid biopsy, others), end-user (hospitals, diagnostic laboratories, diagnostic and imaging centers, academic and research institutes, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Test Type

Dominant Subsegment: Imaging Tests.

The imaging tests segment accounted for 50% of the Lung Cancer Diagnostics market in 2025. Imaging tests dominate because computed tomography, including low-dose computed tomography screening and diagnostic computed tomography, together with positron emission tomography, chest radiography, and magnetic resonance imaging, are central to the detection, diagnosis, and staging of lung cancer and generate very high volumes. The expansion of low-dose computed tomography screening in high-risk populations, the workup of pulmonary nodules, and staging with positron emission tomography drive extensive imaging activity, generating the largest share of diagnostic use. The laboratory tests segment, including biopsy and cytology, immunohistochemistry, molecular and biomarker testing, liquid biopsy, and sputum cytology, is a large and rapidly growing segment driven by the expansion of biomarker-guided therapy, comprehensive molecular profiling, and liquid biopsy, and it is central to precision treatment. Nonetheless, the central role of imaging in screening, detection, diagnosis, and staging secures the leadership of the imaging tests segment across the forecast period, with laboratory and molecular testing growing strongly alongside.

By Product Type

Dominant Subsegment: Reagents and Kits.

The reagents and kits segment accounted for 65% of the Lung Cancer Diagnostics market in 2025. Reagents and kits dominate because diagnostic testing consumes assay-specific reagents, antibodies, probes, stains, and kits for cytology and biopsy processing, histopathology, immunohistochemistry, molecular testing, and liquid biopsy, generating recurring, per-test demand that exceeds one-time instrument purchases in aggregate revenue. The rapid growth of biomarker and companion diagnostic testing, including EGFR, ALK, KRAS G12C, and PD-L1, and comprehensive next-generation sequencing and liquid biopsy, expands high-value reagent and kit consumption. Leading suppliers such as Roche through Ventana and Foundation Medicine, Thermo Fisher through Oncomine, QIAGEN through TheraScreen, and molecular and liquid biopsy specialists generate substantial recurring revenue. The instruments segment, including imaging systems, sequencing platforms, immunohistochemistry and molecular analyzers, and bronchoscopy systems, represents important capital revenue and anchors reagent pull-through. Nonetheless, the continuous, volume-driven consumption of reagents and kits, tied directly to testing volume, secures the segment's leadership across the forecast period.

Lung Cancer Diagnostics Market Region Analysis

North America accounted for 42% of the global Lung Cancer Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced diagnostic and oncology infrastructure, established low-dose computed tomography screening, rapid adoption of biomarker and liquid biopsy testing, strong reimbursement, and the presence of leading manufacturers. The United States leads on the strength of established screening recommendations, advanced imaging, pathology, and molecular testing capacity, rapid adoption of companion diagnostics and comprehensive sequencing, and the presence of major players including Roche through Foundation Medicine, Thermo Fisher Scientific, Guardant Health, Illumina, and Natera. Disease burden is substantial, with a large lung cancer population and a history of high smoking prevalence. The regulatory environment is well established, with the Food and Drug Administration providing clearance and companion diagnostic pathways and having approved multiple lung cancer companion diagnostics, including blood-based tests. Reimbursement supports oncology diagnostics and screening, and strong research infrastructure further reinforces the market. This combination of screening, precision oncology adoption, and manufacturer presence reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Lung Cancer Diagnostics market. The region's elevated CAGR is driven by the highest global burden of lung cancer, large populations, rising screening, and growing healthcare investment across China, Japan, South Korea, India, and Southeast Asia. China bears the largest share of the global lung cancer burden, driven by high smoking prevalence and air pollution, and rising diagnosis, expanding screening, and growing access to targeted therapies and companion diagnostics drive substantial demand. Rising healthcare access, expanding imaging and laboratory capacity, and the growing availability of molecular and liquid biopsy testing further increase testing, and domestic manufacturers are expanding offerings. Both multinational and regional companies are expanding their presence. Government cancer control initiatives and rising awareness reinforce growth. The combination of the highest disease burden, large populations, expanding screening and access, and growing precision oncology positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 42% of the global Lung Cancer Diagnostics market revenue in 2025. The United States dominates the region on the strength of established screening, advanced diagnostic infrastructure, rapid adoption of biomarker and liquid biopsy testing, and the presence of leading manufacturers, while Canada contributes through its cancer care networks and Mexico expands access within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom. Growth is supported by a high disease burden, expanding lung cancer screening, growing biomarker testing, and the presence of major manufacturers, while the European In Vitro Diagnostic Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region and bears the highest global burden of lung cancer, propelled by China's large population and disease burden, rising screening, and expanding healthcare access across Japan, South Korea, India, and Southeast Asia. Growing imaging and molecular testing capacity and expanding access to targeted therapies broaden adoption.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of lung cancer, improving imaging and laboratory capacity, and expanding healthcare investment are broadening adoption, while investment in cancer diagnostics supports growth.

Lung Cancer Diagnostics Market Competitive Landscape

The Lung Cancer Diagnostics market is classified as Moderately Concentrated. A group of large diagnostics and imaging companies holds significant revenue across imaging, pathology, immunohistochemistry, and molecular testing, led by Roche through Ventana and Foundation Medicine, Thermo Fisher Scientific, QIAGEN, and Agilent through Dako, while molecular and liquid biopsy specialists including Guardant Health, Illumina, and Natera, broad diagnostics players such as Abbott, pathology leaders such as Danaher through Leica Biosystems, and lung-focused companies such as Biodesix hold significant positions, and a field of specialized and regional players competes across the market. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, spanning large imaging, pathology, and molecular diagnostics companies alongside specialized liquid biopsy, lung-focused, and regional players.
• Leading players: Roche through Ventana and Foundation Medicine, Thermo Fisher Scientific, QIAGEN, and Agilent through Dako anchor the top tier, with Guardant Health, Illumina, Abbott, Natera, Danaher, and Biodesix holding significant positions.
• Geographic reach: Leaders operate global commercial, manufacturing, and support networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players hold broad portfolios spanning imaging, immunohistochemistry, molecular testing, next-generation sequencing, and liquid biopsy.
• Pipeline strength: Deep pipelines in companion diagnostics, comprehensive sequencing, liquid biopsy, and artificial intelligence-assisted imaging and pathology.
• Strategic partnerships: Companion diagnostic collaborations with pharmaceutical companies, tied to targeted therapy approvals, shape the competitive landscape.
• M&A activity: Consolidation continues across molecular diagnostics, liquid biopsy, and pathology, exemplified by Roche's ownership of Foundation Medicine.
• Manufacturing capabilities: Large-scale reagent, antibody, and consumable manufacturing and instrument production are key competitive strengths and barriers to entry.
• Innovation focus: Companion and molecular diagnostics, liquid biopsy, comprehensive sequencing, artificial intelligence-assisted imaging and digital pathology, and minimal residual disease testing.

Lung Cancer Diagnostics Market Recent Developmental Activities

In 2023 and 2024, the Food and Drug Administration approved and expanded blood-based companion diagnostics, including Guardant360 CDx and FoundationOne Liquid CDx, tied to targeted therapies in non-small cell lung cancer. Strategic significance: Establishes liquid biopsy as a mainstream companion diagnostic and expands minimally invasive molecular testing.

In 2023 and 2024, KRAS G12C inhibitors sotorasib and adagrasib expanded in non-small cell lung cancer, supported by companion diagnostics including Guardant360 CDx. Strategic significance: Adds KRAS G12C testing to the required biomarker panel and drives companion diagnostic adoption.

Lung Cancer Diagnostics Market Segmentation

Lung Cancer Diagnostics Market by Test Type

• Imaging Tests (Low-Dose CT, Diagnostic CT, PET-CT, Chest X-Ray, MRI, Others)
• Laboratory Tests (Biopsy and Cytology, Immunohistochemistry, Molecular and Biomarker Testing, Liquid Biopsy, Sputum Cytology, Others)

Lung Cancer Diagnostics Market by Product Type

• Reagents and Kits
• Instruments

Lung Cancer Diagnostics Market by Technology

• Imaging
• Bronchoscopy
• Histopathology and Immunohistochemistry
• Molecular Diagnostics (PCR and Next-Generation Sequencing)
• Liquid Biopsy
• Others

Lung Cancer Diagnostics Market by End-User

• Hospitals
• Diagnostic Laboratories
• Diagnostic and Imaging Centers
• Academic and Research Institutes
• Others

Lung Cancer Diagnostics Market by Geography

• North America Lung Cancer Diagnostics Market
• United States Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Canada Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Mexico Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Europe Lung Cancer Diagnostics Market
• Germany Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• United Kingdom Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• France Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Italy Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Spain Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of Europe Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Asia-Pacific Lung Cancer Diagnostics Market
• China Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Japan Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• India Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Australia Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• South Korea Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Rest of the World (RoW) Lung Cancer Diagnostics Market
• Middle East Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• Africa Lung Cancer Diagnostics Market Size in USD million (2023-2034)
• South America Lung Cancer Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Lung Cancer Diagnostics Market Report Study

• Market size analysis for the current lung cancer diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global lung cancer diagnostics market.
• Various opportunities available for competitors in the lung cancer diagnostics market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current lung cancer diagnostics market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for lung cancer diagnostics market growth in the future?

Target audience who can benefit from this lung cancer diagnostics market report study

• Lung Cancer Diagnostics product providers
• Research organizations and consulting companies
• Lung Cancer Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in lung cancer diagnostics products
• Various end-users who want to know more about the lung cancer diagnostics market and the latest technological developments in the lung cancer diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Lung Cancer Diagnostics market?

The Lung Cancer Diagnostics market is projected to expand at a CAGR of 7.8% during the forecast period of 2026-2034.

Q2. What is the market size of the Lung Cancer Diagnostics market?

The Lung Cancer Diagnostics market is estimated at USD 3.5 billion in 2025 and is projected to reach USD 6.9 billion by 2034.

Q3. Which region dominates the Lung Cancer Diagnostics market?

North America dominated the Lung Cancer Diagnostics market with a 42% share of global revenue in 2025, supported by established low-dose computed tomography screening, advanced diagnostic and oncology infrastructure, rapid adoption of biomarker and liquid biopsy testing, supportive FDA pathways, and the presence of leading manufacturers. Asia-Pacific, which bears the highest global burden of lung cancer, is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Lung Cancer Diagnostics market?

The principal drivers are the rising global incidence of lung cancer, the leading cause of cancer death worldwide; the expansion of low-dose computed tomography screening; the growing role of biomarker and companion diagnostic testing, including EGFR, ALK, KRAS G12C, and PD-L1; and the rapid growth of liquid biopsy and comprehensive sequencing, reinforced by artificial intelligence-assisted imaging and pathology and expanding access in emerging markets.

Q5. Who are the major players in the Lung Cancer Diagnostics market?

The major players include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., Guardant Health, Inc., Illumina, Inc., Abbott Laboratories, Natera, Inc., Danaher Corporation, and Biodesix, Inc., among other active manufacturers profiled in the Competitive Landscape section. Roche through Ventana and Foundation Medicine lead in pathology and profiling, while Guardant Health, Illumina, and Natera lead in molecular and liquid biopsy testing.